HPV vaccination in France: uptake, costs and issues for the National Health Insurance.

Abstract

INTRODUCTION:

Two vaccines for primary prevention of cervical cancer are available in France, Gardasil® and Cervarix®, since 2007 and 2008 respectively. Currently, the French guidelines indicate vaccination of girls aged 14 with a catch-up program for females from 15 to 23 years old. In France, the reimbursement rate for these vaccines is 65% of the vaccine price, resulting in Gardasil® being the fifth highest drug expenditure of the main scheme of the French National Health Insurance in 2008. The purpose of this study is to provide data on vaccination coverage and costs in France until 31 December 2009. In addition, the current vaccination coverage rate is compared with the coverage rates assumed in cost-effectiveness studies.

METHODS:

Data were extracted from the National Health Insurance Information System (SNIIRAM). The SNIIRAM records all reimbursements of medical costs to patients--including drugs--by the French public Health Insurance Schemes since 2004. The analysis was performed for the period of July 2007 until December 2009 using the data of the general scheme of National Health Insurance covering about 88% of the French population, i.e., 56.5 million people. Vaccination rates for one or three doses were determined for the target and catch-up population using the 2009 reference population from the general health insurance scheme as the denominator.

RESULTS:

The cumulative number of doses reached 2,900,000 at the end of 2009. About 1,200,000 girls and young women have been reimbursed for at least one vaccine dose, of these 96.5% females aged 14-23 years. Among the target group, reimbursement for at least one dose remained low, from 50.8% for girls aged 14 years in 2007 to 41.7% and 20.5% for girls aged 14 years in 2008 and 2009 respectively. In terms of complete vaccination, only 33.3% of girls of the age of 14 years in 2007 and 23.7% in 2008 were reimbursed for 3 doses of HPV vaccine. The maximum uptake in the catch-up group for both 1 and 3 doses was observed for women born in 1992 (15 years in 2007) with 52.5% and 35.6% respectively.

CONCLUSION:

Low rates of coverage have been observed both in the target and catch-up groups in France. Considering this, the cost-effectiveness of vaccination in combination with opportunistic screening or organized screening needs to be re-evaluated.

• Authors: Jean-Paul Fagot, Aurélie Boutrelle, Philippe Ricordeau, Alain Weill, Hubert Allemand
• Journal: Vaccine (Vaccine) Vol. 29 Issue 19 Pg. 3610-6 (Apr 27 2011) ISSN: 1873-2518 [Electronic] Netherlands
• PMID: 21382486 (Publication Type: Journal Article)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
• Papillomavirus Vaccines
• human papillomavirus vaccine, L1 type 16, 18

Topics

• Adolescent
• Adult
• Cost-Benefit Analysis
• Female
• France
• Health Care Costs
• Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
• Humans
• Immunization Programs (economics, statistics & numerical data)
• National Health Programs (economics)
• Papillomavirus Infections (prevention & control)
• Papillomavirus Vaccines (economics)
• Uterine Cervical Neoplasms (prevention & control, virology)
• Vaccination (economics, statistics & numerical data)
• Young Adult